Citadel Advisors
PPCB

Citadel Advisors’s Propanc Biopharma PPCB Stock Holding History

Citadel Advisors’s Portfolio PPCB Stock Details PPCB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.1K Buy
+12,090
New +$26.1K ﹤0.01% 13423

Other funds holding PPCB

Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
CIAM
Caitong International Asset Management Hong Kong $729M AUM 1,176.98% 1-Year Est. Return

Citadel Advisors's PPCB Position: Q2 2026 in Review

Citadel Advisors opened a new position in Propanc Biopharma (PPCB) in Q2 2026: 12,090 shares worth $18.1K. The stake represents ﹤0.01% of the portfolio and ranks #13423 among its holdings.

4 funds tracked by Wall St. Rank hold PPCB as of Q2 2026.

  • Citadel Advisors held 12,090 shares of Propanc Biopharma worth $18.1K as of Q2 2026.
  • Propanc Biopharma was a new Citadel Advisors position in Q2 2026.
  • Propanc Biopharma made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #13423 holding.
  • 4 funds tracked by Wall St. Rank held Propanc Biopharma as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.